Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand Pharma join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. See why this ...
pharmaphorum11m
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...